InvestmentUpdated on 15 July 2025
Advanced Therapys for liver diseases
About
Liver fibrosis in the form of MASH is the most common liver disorder worldwide, will affect approximately 25% of world´s population (1 in 4)
TAM of 27 B
Currently, only one drug has received provisional FDA approval for MASH after 1 year of clinical trial. with some concerns: results after completion of the 5-year clinical trial / optimization of dosing and timing / long term safety / very expensive / not covered by Health Systems for a chronic treatment
But oru approach in totally new, Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcription factor that regulates the expression of multiple defensive genes.NRF2 makes heterodimers with small MAFs and activates genes containing the Antioxidant response Element (ARE).
Similar opportunities
Service
R&D and Clinical Genomic Services
- Development
- Cosmetic industry
- Laboratory industry
- Pharmaceutical industry
Marc del Pino
Southern Europe Sales Manager at GENEWIZ
Barcelona, Spain
Service
- Consulting
- Development
- Health innovation
- Laboratory industry
- Pharmaceutical industry
Kseniya Tymko
Business Development Director at Pharmbiotest Poland Ltd
Grudziadz, Poland
Service
Clinical Trial Supply & Logistics Services
- Development
- Manufacturing
- Pharmaceutical industry
Marc Brehme
Founder & Managing Director at M-B-V-C
Vienna, Austria